1月6日港股通创新药ETF工银(159217)遭净赎回926.56万元

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced significant net redemptions, indicating a trend of outflow in the cross-border ETF market [1][2]. Group 1: Fund Performance - As of January 6, the fund's latest scale is 50.48 billion yuan, with a net outflow of 926.56 million yuan on that day, representing 0.18% of the previous day's scale [1]. - Over the past five days, the fund faced net redemptions totaling 942.76 million yuan, ranking 16th out of 207 in cross-border ETF net outflows [1]. - Year-to-date, the fund's share count decreased by 0.32% from 37.63 billion shares on December 31, 2025, while its scale increased by 6.24% [2]. Group 2: Liquidity and Trading Activity - The cumulative trading amount over the last 20 trading days reached 87.66 billion yuan, with an average daily trading amount of 4.38 billion yuan [2]. - In the first two trading days of the year, the cumulative trading amount was 11.7 billion yuan, averaging 5.85 billion yuan per day [2]. Group 3: Fund Management and Holdings - The current fund managers are Liu Weilin and Jiao Wendong, with returns of 34.57% and 53.37% respectively during their management periods [2]. - Major holdings in the fund include companies like 百济神州 (10.84%), 康方生物 (10.77%), and 信达生物 (10.43%), with significant market values for each [2].